{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-115119","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.939472+00:00","generated_at":"2026-05-15T09:36:23.170044+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Larimar reports Q4 net loss $62.5M; BLA for nomlabofusp on track for June 2026 submission","bullets":["Net loss Q4 2025 $62.5M ($0.73/sh) vs $28.8M ($0.45/sh) in Q4 2024; R&D expenses rose to $59.4M.","Full-year 2025 net loss $165.7M ($2.27/sh) vs $80.6M ($1.32/sh) in 2024.","Cash & equivalents $136.9M at Dec 31, 2025; pro forma $244.5M after Feb 2026 $107.6M offering, runway into Q2 2027.","FDA granted Breakthrough Therapy Designation for nomlabofusp in FA; FDA alignment on FXN as surrogate endpoint.","Phase 3 confirmatory study screening to start Q2 2026; topline open-label data expected Q2 2026; BLA submission June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-115119","json":"https://secwatch.observer/filing/0001193125-26-115119.json","markdown":"https://secwatch.observer/filing/0001193125-26-115119.md","text":"https://secwatch.observer/filing/0001193125-26-115119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526115119/0001193125-26-115119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526115119/lrmr-20260319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:36:23.170044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}